Background: Falls significantly impact morbidity and mortality. The contributing factors to falls are multifactorial and apart from well-documented risk factors, such as age, gender, adverse effects from medications and other comorbidities, chemotherapy-induced peripheral neuropathy (CIPN) is overlooked as a contributing cause in cancer patients. Clinical details: We report a case involving a generally healthy 70-year-old woman who presented with a fall following several cycles of paclitaxel-based chemotherapy for early breast cancer. Outcomes: Currently there is insufficient data to recommend treatment for CIPN. The patient's progressive worsening of paclitaxelinduced peripheral neuropathy and fatigue were deemed to be the main contributing factors to her fall. The scheduled paclitaxel was discontinued prematurely due to the negative impacts on the patient's quality of life outweighing the benefits of completing the course of treatment. This case also highlights the use of a multi-disciplinary approach to optimise patient care and treatment outcome. Conclusion: CIPN may easily be overlooked, especially in the context of assessing risk of falls in patients at risk of CIPN. This could be monitored and managed effectively by the multidisciplinary team.
INTRODUCTION
Falls significantly impact on morbidity and mortality. 1 Contributing factors to falls risk include age, gender, side effects from medications and chronic illnesses (e.g. Parkinson's disease, stroke). 1 In a patient undergoing treatment for cancer, risk of falls is further exacerbated. Chemotherapy-induced peripheral neuropathy (CIPN) is not an uncommon side effect. Chemotherapeutic classes/agents associated with CIPN include platinum analogues, taxanes, epotholones, vinca alkaloids, bortezomib and thalidomide analogues. 2, 3 It can affect 20-40% of patients receiving chemotherapy, depending on treatment protocols (e.g. dose per cycle, cumulative dose, duration of infusion, treatment schedule), concomitant use of other treatments (e.g. neurotoxic agents, radiotherapy), and any pre-existing neuropathy induced by diabetes, thyroid dysfunction, vitamin B 12 deficiency or alcoholism. [2] [3] [4] [5] CIPN refers to any injury, inflammation or degeneration of nerves outside of the brain and spinal cord that typically involve sensory and motor nerve fibres.
2,3 It often begins simultaneously in the hands and feet, giving rise to the characteristic stocking-glove distribution. 2, 3 Signs and symptoms of CIPN vary depending on which nerve fibres have been affected. Damage to sensory nerve fibres may cause paresthesias and dysesthesias, 6 whereas damage to the motor nerves can cause foot or wrist drop and affect balance, strength and activity levels. 2, 3 Damage to the autonomic nerves may result in constipation, urinary retention, incontinence, erectile dysfunction and orthostatic hypotension. 2, 3 Diagnosis of CIPN encompasses objective clinical examinations and subjective assessments. Although standardised methods to assess and grade CIPN have not been established to date, the National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) has been widely used and has been adopted at our centre (Table 1) . 7 Considering the signs and symptoms of CIPN, patients receiving agents that cause CIPN potentially have an increased risk of falls.
CASE REPORT
A 70-year-old female patient presented with a screendetected lump in her left breast. Subsequently, she was diagnosed with early triple positive breast cancer (19 mm, Grade 2 invasive ductal carcinoma, human epidermal growth factor receptor-2 positive). She then underwent a wide local excision and sentinel node biopsy, and was found to have lymph node-negative disease with no evidence of lymphovascular invasion. The patient reported no family history of cancer, and was generally in good health apart from hypercholesterolemia, treated with atorvastatin 20 mg daily. She was on no other regular medication. The patient was retired, lived with her husband and was independent with daily living requirements. She never smoked and drank a glass of scotch daily. The patient's treatment plan entailed adjuvant chemotherapy after surgery, followed by radiotherapy and hormonal therapy. Due to the low volume of disease, the patient was scheduled to receive weekly intravenous (IV) paclitaxel 147 mg for 12 weeks with 3-weekly IV trastuzumab; loading: 577 mg; maintenance: 430 mg for 51 weeks in total, with single doses of IV dexamethasone 8 mg, IV ranitidine 50 mg, oral loratidine 10 mg as pre-medications and oral metoclopramide 10 mg three times a day when required for nausea as take-home medication.
Unfortunately, prior to the last dose of paclitaxel the patient had a fall outside the oncology unit. No serious injuries were sustained from the fall and the patient stated her knees had 'given way with no warning'. Upon examination, her vital signs were satisfactory (blood pressure 133/80; respiratory rate 18; pulse regular at 70 beats per minute; afebrile).
A neurological examination revealed both sensory and motor neuropathy on both limbs of the patient regarding muscle strength, power, reflexes and sensation, which led to diagnosis of grade 1 peripheral neuropathy and grade 1-2 fatigue according to NCI-CTCAE (Table 1) . 8 The patient was subsequently referred to a physiotherapist for further assessment of balance and muscle strength, and management of fatigue and mobility. The physiotherapist concurred with the doctor's diagnosis that the fall was likely contributed by CIPN and complicated by fatigue. The patient reported there had been a progressive increase of weakness and lethargy from chemotherapy, which included general weakness in the legs, pins and needles on fingers, toes and mouth and occasional gait dysfunction. Although muscle pain and/or weakness may potentially be caused by atorvastatin and dexamethasone, especially in the elderly, it was deemed unlikely since treatment with atorvastatin was long-standing and the patient had no liver function or creatine kinase test abnormality. In addition, the dexamethasone was prescribed as recommended by the eviQ Cancer Treatments Online protocol. 9 There is no evidence to suggest ranitidine, loratidine or metoclopramide may contribute to falls. It was therefore decided to not administer the final dose of paclitaxel due to the potential for further CIPN and fatigue. Her remaining scheduled doses of trastuzumab were able to continue without delay. Despite paclitaxel cessation the patient reported persistent painful neuropathy at a follow-up appointment 4 weeks post fall and amitriptyline 25 mg at night was prescribed. After 5 weeks of amitriptyline therapy, neuropathic pain had mostly resolved and amitriptyline treatment discontinued.
DISCUSSION
Taxanes (docetaxel, paclitaxel and cabazitaxel) 2, 3 act by binding to the beta protein subunits of tubulins. These subunits enhance polymerisation of tubulins to form The risk of CIPN is greatest with paclitaxel. Previous trials reported mild to moderate neurotoxicity in up to 88% of patients and severe toxicity in 5-12% of patients receiving paclitaxel. 10, 11 It primarily affects the sensory fibres but injury to motor neurons is also possible. 3, 10 It is believed that paclitaxel causes disruption of the microtubulin structure leading to impairment of transportation of proteins and other components within the nerve, leading to a 'dying back' neuropathy. 5, 10 Since the neurons to the hands and feet are the longest axons in the human body, and they depend highly on the transportation of nutrients, the distal limbs are the most susceptible to CIPN. Furthermore, taxanes may exert a toxic effect on mitochondria in primary afferent neurons by disrupting the energy supply within the cells, causing sensory axonal degeneration.
5,12
Weekly administration was found to have higher NCI-CTCAE grade 3/4 neurotoxicity incidence than a 3-weekly regimen in one randomised phase III trial; however, a more recent meta-analysis reported the contrary. 11 It is suggested that the risk and severity of CIPN tend to increase with age. 2 Our patient's age, use of a neurotoxic agent (paclitaxel given weekly) and fatigue from treatment contributed to the increased risk of falls. Management of CIPN in clinical practice has included dose reduction, delays or treatment discontinuation; eviQ protocol suggests 25% dose reduction for NCI-CTCAE grade 2 peripheral neuropathy and a further 25% reduction if neuropathy persists. 9 Studies have suggested that 50-80% of patients have symptoms persisting after 1 year but with much lesser severity.
5,11
Limited data is available on the duration of paclitaxelinduced CIPN after therapy discontinuation or completion. 5 It is important to monitor CIPN in cancer patients receiving neurotoxic agents and to consider the need to initiate CIPN treatment. 7 While there is insufficient data to formally recommend any agent to treat CIPN, duloxetine may be considered based on the available evidence. 4, 5 Tricyclic antidepressants (e.g. nortriptyline and amitriptyline), gabapentin and pregabalin may be used in view of their benefits in other forms of neuropathic pain, given limited treatment options for CIPN. 4, 5 The general management of peripheral neuropathy is challenging. The mechanisms of CIPN are not fully elucidated and different chemotherapeutic agents often exhibit diverse means of causing neurotoxicity. 5, 11 More scientifically robust studies are warranted to identify and evaluate the safety and efficacy of new and existing agents for the treatment of CIPN. Studies on the pathogenesis of CIPN, genetic variation and predisposition would also be of great value in providing novel therapeutic and screening targets.
As demonstrated in this case CIPN can have a negative impact on quality of life. It is therefore important to consider CIPN as an additional contributing factor to falls in the cancer setting, and address potential dose adjustment of the offending agent(s) and requirements for additional CIPN treatment.
As demonstrated in this case a multidisciplinary approach that insures pre-and post-treatment assessment by pharmacy, medical, nursing and allied health practitioners who are aware of CIPN and its consequences offers the optimum means to minimise adverse outcomes. The oncology pharmacist must be able to identify and offer potential solutions (dose reductions, alterations to protocols etc.) to medication regimens where CIPN may be a problem.
CONCLUSION
CIPN may easily be overlooked, especially in the context of assessing risk of falls in patients at risk of CIPN. This could be monitored and managed effectively by a multidisciplinary team.
